Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:receptor_tyrosine_kinase
gptkb:drug |
| gptkbp:approvalYear |
2017
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L01ED10
|
| gptkbp:brand |
gptkb:Alunbrig
|
| gptkbp:CASNumber |
1197953-54-0
|
| gptkbp:chemicalClass |
aminopyridine derivative
|
| gptkbp:developedBy |
gptkb:Ariad_Pharmaceuticals
|
| gptkbp:hasMolecularFormula |
C29H39N7O2
|
| https://www.w3.org/2000/01/rdf-schema#label |
Brigatinib
|
| gptkbp:indication |
ALK-positive metastatic non-small cell lung cancer
|
| gptkbp:KEGGID |
gptkb:D10841
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
ALK inhibitor
ROS1 inhibitor |
| gptkbp:proteinTarget |
gptkb:anaplastic_lymphoma_kinase
ROS1 |
| gptkbp:PubChem_CID |
gptkb:CHEMBL3137347
gptkb:DB12267 57379345 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea fatigue hypertension cough pneumonitis |
| gptkbp:UNII |
Q1F7A44B2F
|
| gptkbp:usedFor |
gptkb:non-small_cell_lung_cancer
|
| gptkbp:bfsParent |
gptkb:Non-Small_Cell_Lung_Cancer
|
| gptkbp:bfsLayer |
6
|